Midcap ups bioMérieux to 'buy' on 'exceptional' U.S. flu season

Biomerieux SA

20/01/2026 10:58

** TP ICAP Midcap upgrades French biotechonology firm bioMérieux BIM.PA to "buy" from "hold", citing a severe flu season in the U.S. as a positive catalyst for the group

** It points to the U.S. CDC data showing hospitalisations at their highest since 2010-2011, with an expert calling it "one of the worst since before COVID"

** This trend is seen benefiting bioMérieux's BioFire division, whose respiratory panels could see double-digit growth in the fourth quarter of 2025, TP ICAP Midcap adds

** It says the severe flu season should help the company reach the upper end of its 2025 revenue guidance or even exceed it, offsetting persistent weakness in the Chinese market

** Out of 12 analysts covering Biomerieux, seven rate the stock "strong buy" or "buy,"​ five rate "hold" and no analysts rate the stock "strong sell" or "sell" - LSEG data

 (Reporting by Mathias de Rozario in Gdansk)

 ((mathias.derozario@thomsonreuters.com))